Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $110000.0.

  • Inhibrx Biosciences' Receivables - Net fell 8363.1% to $110000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $110000.0, marking a year-over-year decrease of 8363.1%. This contributed to the annual value of $397000.0 for FY2024, which is 4897.17% down from last year.
  • As of Q3 2025, Inhibrx Biosciences' Receivables - Net stood at $110000.0, which was down 8363.1% from $237000.0 recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Receivables - Net ranged from a high of $778000.0 in Q4 2023 and a low of $110000.0 during Q3 2025
  • Moreover, its 3-year median value for Receivables - Net was $271000.0 (2024), whereas its average is $376857.1.
  • The largest annual percentage gain for Inhibrx Biosciences' Receivables - Net in the last 5 years was 1254.61% (2025), contrasted with its biggest fall of 8363.1% (2025).
  • Over the past 3 years, Inhibrx Biosciences' Receivables - Net (Quarter) stood at $778000.0 in 2023, then tumbled by 54.24% to $356000.0 in 2024, then crashed by 69.1% to $110000.0 in 2025.
  • Its Receivables - Net was $110000.0 in Q3 2025, compared to $237000.0 in Q2 2025 and $214000.0 in Q1 2025.